157 results on '"Sottotetti, Federico"'
Search Results
2. Vitamin B12 status in hospitalised cancer patients: Prevalence and clinical implications of depletion and hypervitaminosis
3. Fast quantification of extracellular vesicles levels in early breast cancer patients by Single Molecule Detection Array (SiMoA)
4. Raman analysis of microcalcifications in male breast cancer
5. Mental health and risk perception among Italian healthcare workers during the second month of the Covid-19 pandemic
6. Impressive and Prolonged Response with Lenvatinib in a Highly Pretreated Patient with Metastatic Clear Cell Renal Cancer
7. Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study
8. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer
9. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study
10. Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR+/HER2– breast cancer treated with CDK4/6 inhibitors and endocrine therapy
11. Smoking Habit and Respiratory Function Predict Patients’ Outcome after Surgery for Lung Cancer, Irrespective of Histotype and Disease Stage
12. Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2– metastatic breast cancer: a prospective, monocentric study
13. Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series
14. Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
15. Small bowel villous atrophy due to immune-checkpoint inhibitors: report of two cases and literature review
16. The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
17. Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience
18. Intravenous or Oral Vinorelbine Plus Capecitabine As First-Line Treatment in HER2– Metastatic Breast Cancer: Joint Analysis of 2 Consecutive Prospective Phase II Trials
19. Tackling the clinical complexity of breast cancer
20. Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study
21. Fast quantification of extracellular vesicles levels in early breast cancer patients by Single Molecule Detection Array (SiMoA)
22. Preoperative Systemic Inflammatory Biomarkers Are Independent Predictors of Disease Recurrence in ER+ HER2- Early Breast Cancer
23. Validation of an LC–MS/MS method for the determination of epirubicin in human serum of patients undergoing Drug Eluting Microsphere-Transarterial Chemoembolization (DEM-TACE)
24. Leptomeningeal carcinomatosis and breast cancer: a systematic review of current evidence on diagnosis, treatment and prognosis
25. Acute Thrombocytopenia: An Unusual Complication Occurring After Drug-Eluting Microspheres Transcatheter Hepatic Chemoembolization
26. Raman spectroscopy on microcalcifications reveals peculiar differences between male and female breast cancer
27. Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study
28. Impact of COVID-19 Outbreak on Cancer Patient Care and Treatment: Data from an Outpatient Oncology Clinic in Lombardy (Italy)
29. Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer
30. Palbociclib in metastatic breast cancer: current evidence and real-life data
31. Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience
32. Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma
33. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients
34. Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program
35. Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?
36. Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant
37. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
38. PO62 FIRST LINE TRASTUZUMAB-BASED THERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS PRESENTING WITH DE NOVO OR RECURRENT DISEASE: A MULTICENTER RETROSPECTIVE COHORT STUDY
39. First line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients (MBC) presenting with de novo or recurrent disease.
40. Does agent sequencing matter across multiple lines of chemotherapy in metastatic breast cancer (MBC)?: A single institution retrospective analysis of 550 women.
41. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
42. Treatment of Chronic Hepatitis C in a Patient Affected by Systemic Sclerosis
43. PO62 DIFFERENT PATTERNS OF TREATMENT WITH ALBUMIN-BOUND PACLITAXEL (NAB-PACLITAXEL) FOR TARGETED CHEMOTHERAPY IN METASTATIC BREAST CANCER: A MULTICENTER ITALIAN EXPERIENCE ON 125 WOMEN
44. PO56 TRIPLE NEGATIVE AND HORMONE-NEGATIVE/HER2-POSITIVE BREAST CANCER: WHICH THE WORST FOR WOMEN WITH METASTATIC DISEASE? A MONO-INSTITUTIONAL RETROSPECTIVE ANALYSIS ON 460 PATIENTS
45. Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians
46. FENOTIPO TUMORALE ED ESPOSIZIONI OCCUPAZIONALI: RISULTATI DI UNO STUDIO PILOTA SULLA NEOPLASIA POLMONARE.
47. Multiple chemotherapy (CT) lines in metastatic breast cancer (MBC): Which survival benefit for women with hormone receptor (HR)-positive disease?
48. Benefit of continuing trastuzumab beyond progression in her2-positive metastatic breast cancer (mbc) is independent of the chemotherapy partner: message from a single-centre retrospective study
49. Which benefit from subsequent chemotherapy lines beyond the second for women with metastatic breast cancer? Evidence from a single-center retrospective analysis of survivorship
50. Acute Thrombocytopenia: An Unusual Complication Occurring After Drug-Eluting Microspheres Transcatheter Hepatic Chemoembolization
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.